David Allen
NPI 1487672986 · Specialist · Ogden, UT
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1487672986
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Sex
- Male
- Sole proprietor
- No
- License
- 53160261205 (UT)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
6,197 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 2,743 | $6 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 1,066 | $89 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 1,040 | $57 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 535 | $126 |
| Biopsy of Related Skin Growth, First Growth11102 | 245 | $90 |
| Destruction of Skin Growth, 1-14 Growths |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 26 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Triamcinolone Acetonide | 407 | 265 |
| Ketoconazole | 210 | 99 |
| Fluorouracil | 129 | 102 |
| Clindamycin Phosphate | 122 | 66 |
| Fluocinonide | 99 | 58 |
| Desonide | 69 | 62 |
| Clobetasol Propionate | 67 | 38 |
| Metronidazole | 66 | 41 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$543 across 36 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-07-17
- Last updated
- 2022-05-11
- Certified
- 2022-05-11
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.